China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that a Chinese clinical study for MaiLi Extreme, an injectable lidocaine-containing sodium hyaluronate by its UK subsidiary Sinclair, has successfully met its primary endpoint, demonstrating good safety data. The study aimed to evaluate the efficacy and safety of MaiLi Extreme injections into the facial periosteal plane and/or subcutaneous adipose tissue for the correction of mild to severe chin retraction.
The MaiLi series of products was introduced to the European market in 2021, following the attainment of the CE mark in 2020. MaiLi Extreme stands out within the series for its high concentration of hyaluronic acid and robust filling capabilities, enabling immediate filling and contouring effects that quickly address chin retraction post-injection.- Flcube.com
